loading
前日終値:
$0.7499
開ける:
$0.7493
24時間の取引高:
891.43K
Relative Volume:
0.52
時価総額:
$50.58M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-37.33
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
+19.26%
1か月 パフォーマンス:
+12.94%
6か月 パフォーマンス:
-31.54%
1年 パフォーマンス:
-54.90%
1日の値動き範囲:
Value
$0.7455
$0.78
1週間の範囲:
Value
$0.61
$0.78
52週間の値動き範囲:
Value
$0.40
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1155)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
121
Name
Twitter
@cytomxinc
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

CTMX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
0.7466 50.58M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.84 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.37 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.96 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.63 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
253.95 26.16B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-14 再開されました Piper Sandler Overweight
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
08:54 AM

CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com

08:54 AM
pulisher
Apr 15, 2025

CytomX Therapeutics (NASDAQ:CTMX) Now Covered by Piper Sandler - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Piper Sandler sets CytomX stock target at $2.50, rates Overweight By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX) - The Globe and Mail

Apr 14, 2025
pulisher
Apr 14, 2025

Piper Sandler sets CytomX stock target at $2.50, rates Overweight - Investing.com

Apr 14, 2025
pulisher
Apr 12, 2025

New Outlook On CytomX Therapeutics Inc - stocksregister.com

Apr 12, 2025
pulisher
Apr 12, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 09, 2025

CytomX Therapeutics Inc (NASDAQ: CTMX) 5.47% Incline Turns Investors Away - stocksregister.com

Apr 09, 2025
pulisher
Apr 05, 2025

Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter

Apr 01, 2025
pulisher
Mar 26, 2025

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN

Mar 26, 2025
pulisher
Mar 23, 2025

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN

Mar 23, 2025
pulisher
Mar 21, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 20, 2025

Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 13, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025
pulisher
Mar 11, 2025

CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter

Mar 10, 2025
pulisher
Mar 08, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Cytomx Therapeutics Inc (CTMX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ogden Christopher
Chief Financial Officer
Mar 18 '25
Sale
0.60
8,551
5,122
201,026
Chu Yu-Waye
Chief Medical Officer
Mar 18 '25
Sale
0.60
4,025
2,411
135,725
ROWLAND LLOYD A
General Counsel
Mar 18 '25
Sale
0.60
10,203
6,112
120,594
BELVIN MARCIA
SVP, Chief Scientific Officer
Mar 18 '25
Sale
0.60
19,512
11,688
248,636
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
123,237
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
大文字化:     |  ボリューム (24 時間):